Ranawaya R - Search Results

Year	Number of Results
1990	1
1991	2
2002	1
2004	1
2005	1
2006	2
2008	1
2009	3
2010	1
2011	1
2012	1
2014	2
2015	1
2024	0

1

Smart watch accelerometry for analysis and diagnosis of tremor.

Wile DJ, Ranawaya R, Kiss ZH. Wile DJ, et al. Among authors: ranawaya r. J Neurosci Methods. 2014 Jun 15;230:1-4. doi: 10.1016/j.jneumeth.2014.04.021. Epub 2014 Apr 23. J Neurosci Methods. 2014. PMID: 24769376

2

Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.

Postuma RB, Espay AJ, Zadikoff C, Suchowersky O, Martin WR, Lafontaine AL, Ranawaya R, Camicioli R, Lang AE. Postuma RB, et al. Among authors: ranawaya r. Neurology. 2006 Jun 27;66(12):1941-3. doi: 10.1212/01.wnl.0000219815.83681.f7. Neurology. 2006. PMID: 16801668 Clinical Trial.

3

Increased intestinal permeability and Parkinson disease patients: chicken or egg?

Salat-Foix D, Tran K, Ranawaya R, Meddings J, Suchowersky O. Salat-Foix D, et al. Among authors: ranawaya r. Can J Neurol Sci. 2012 Mar;39(2):185-8. doi: 10.1017/s0317167100013202. Can J Neurol Sci. 2012. PMID: 22343151

4

Fatigue in levodopa-naive subjects with Parkinson disease.

Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S; Parkinson Study Group ELLDOPA Investigators. Schifitto G, et al. Neurology. 2008 Aug 12;71(7):481-5. doi: 10.1212/01.wnl.0000324862.29733.69. Neurology. 2008. PMID: 18695158 Free PMC article. Clinical Trial.

5

Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies.

Taylor AE, Lang AE, Saint-Cyr JA, Riley DE, Ranawaya R. Taylor AE, et al. Among authors: ranawaya r. Clin Neuropharmacol. 1991 Feb;14(1):62-77. doi: 10.1097/00002826-199102000-00005. Clin Neuropharmacol. 1991. PMID: 2029694

6

Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.

Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE; Parkinson Study Group DATATOP and PRECEPT investigators. Marras C, et al. Mov Disord. 2011 Mar;26(4):608-13. doi: 10.1002/mds.23581. Epub 2011 Feb 1. Mov Disord. 2011. PMID: 21287602

7

Psychogenic dyskinesias in patients with organic movement disorders.

Ranawaya R, Riley D, Lang A. Ranawaya R, et al. Mov Disord. 1990;5(2):127-33. doi: 10.1002/mds.870050206. Mov Disord. 1990. PMID: 2325674

8

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group DATATOP and PRECEPT investigators. Marras C, et al. Mov Disord. 2009 Dec 15;24(16):2370-8. doi: 10.1002/mds.22828. Mov Disord. 2009. PMID: 19908310 Clinical Trial.

9

Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.

Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators; Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, Goetz C. Schwid SR, et al. Mov Disord. 2010 Sep 15;25(12):1801-8. doi: 10.1002/mds.23006. Mov Disord. 2010. PMID: 20669311 Clinical Trial.

10

A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators. Olanow CW, et al. N Engl J Med. 2009 Sep 24;361(13):1268-78. doi: 10.1056/NEJMoa0809335. N Engl J Med. 2009. PMID: 19776408 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

18 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year